Therapeutic drug monitoring of cyclosporine (Q35711356)

9 August 2017

1 reference

title

Therapeutic drug monitoring of cyclosporine (English)

1 reference

9 August 2017

1 reference

Jorga A

1

1 reference

9 August 2017

Holt DW

series ordinal

2

1 reference

9 August 2017

Johnston A

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Transplantation Proceedings

9 August 2017

published in

1 reference

9 August 2017

volume

36

1 reference

9 August 2017

issue

2 Suppl

1 reference

9 August 2017

page(s)

396S-403S

1 reference

Update for the Canadian Multicentre Trial of Cyclosporine in Renal Allografts

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Biological effects of cyclosporin A: A new antilymphocytic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The history of cyclosporin A (Sandimmune) revisited: another point of view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Reduced cyclosporine absorption preceded acute allograft rejection in a child with a liver transplant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The effect of vehicle on the oral absorption of cyclosporin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Therapeutic drug monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The use of therapeutic drug monitoring to optimise immunosuppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Limited sampling strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Enhancement of the oral absorption of cyclosporin in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Pharmacokinetic validation of neoral absorption profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The temporal profile of calcineurin inhibition by cyclosporine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine rapamycin regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Neoral C-2 monitoring in cardiac transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Neoral C(2) monitoring in pediatric liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The influence of haematocrit on blood cyclosporin measurements in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Sample pretreatment to minimize interference from whole blood in the radioimmunoassay for cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

The United Kingdom Cyclosporin Quality Assessment Scheme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Cyclosporin assay techniques. Accuracy and reproducibility variables impacting on measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Optimizing the use of cyclosporine in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Monitoring new immunosuppressive agents. Are the methods adequate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Current opinions on therapeutic drug monitoring of immunosuppressive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Cyclosporin: revisions in monitoring guidelines and review of current analytical methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Bioequivalence criteria for cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Generic substitution for cyclosporine: what should we be looking for in new formulations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Which cyclosporin formulation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Relevance of pharmacokinetics in narrow therapeutic index drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Recommendations for bioequivalence testing of cyclosporine generics revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

An individual bioequivalence approach to compare the intrasubject variability of two ciclosporin formulations, SangCya and Neoral.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Neoral absorption profiling: an evolution in effectiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Recommendations for the implementation of Neoral C(2) monitoring in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Patient management by Neoral C(2) monitoring: an international consensus statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

Blood cyclosporin concentrations and renal allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2004.01.013

10.1016/J.TRANSPROCEED.2004.01.013

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference